Narek Shaverdian

Narek Shaverdian

Auto-generated profile, based on publicly available information

Narek Shaverdian

Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
NSNarek Shaverdian
Narek Shaverdian
ALAaron E Lisberg
Aaron E Lisberg
KBKrikor Bornazyan
Krikor Bornazyan
DVDarlene Veruttipong
Darlene Veruttipong
JGJonathan W Goldman
Jonathan W Goldman
PLPercy Lee
Percy Lee

1 January 2019 in Advances in Radiation Oncology
Verified
Journal Article
Open access
SRStephen A. Rosenberg
Stephen A. Rosenberg
LHLauren E. Henke
Lauren E. Henke
NSNarek Shaverdian
Narek Shaverdian
KMKathryn Mittauer
Kathryn Mittauer
AWAndrzej P. Wojcieszynski
Andrzej P. Wojcieszynski
MBMichael Bassetti
Michael Bassetti
Daily magnetic resonance (MR)-guided radiation has the potential to improve stereotactic body radiation therapy (SBRT) for tumors of the liver. Magnetic resonance imaging (MRI) introduces unique variables that are untested clinically: electron return effect, MRI geometric distortion, MRI to radiation therapy isocenter uncertainty, multileaf collimator position error, and uncertainties with voxel size and tracking. All could lead to increased toxicity and/or local recurrences with SBRT. In this multi-institutional study, we hypothesized that direct visualization provided by MR guidance could allow the use of small treatment volumes to spare normal tissues while maintaining clinical outcomes despite the aforementioned uncertainties in MR-guided treatment. Patients with primary liver tumors or metastatic lesions treated with MR-guided liver SBRT were reviewed at 3 institutions. Toxicity was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4. Freedom from local progression (FFLP) and overall survival were analyzed with the Kaplan-Meier method and χ2 test. The study population consisted of 26 patients: 6 hepatocellular carcinomas, 2 cholangiocarcinomas, and 18 metastatic liver lesions (44% colorectal metastasis). The median follow-up was 21.2 months. The median dose delivered was 50 Gy at 10 Gy/fraction. No grade 4 or greater gastrointestinal toxicities were observed after treatment. The 1-year and 2-year overall survival in this cohort is 69% and 60%, respectively. At the median follow-up, FFLP for this cohort was 80.4%. FFLP for patients with hepatocellular carcinomas, colorectal metastasis, and all other lesions were 100%, 75%, and 83%, respectively. This study describes the first clinical outcomes of MR-guided liver SBRT. Treatment was well tolerated by patients with excellent local control. This study lays the foundation for future dose escalation and adaptive treatment for liver-based primary malignancies and/or metastatic disease.

27 October 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RCRhea N. Coler
Rhea N. Coler
SBSusan L. Baldwin
Susan L. Baldwin
NSNarek Shaverdian
Narek Shaverdian
SBSylvie Bertholet
Sylvie Bertholet
SRSteven J. Reed
Steven J. Reed
NHNeal Van Hoeven
Neal Van Hoeven
Safe, effective adjuvants that enhance vaccine potency, including induction of neutralizing Abs against a broad range of variant strains, is an important strategy for the development of seasonal influenza vaccines which can provide optimal protection, even during seasons when available vaccines are not well matched to circulating viruses. We investigated the safety and ability of Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE), a synthetic Toll-like receptor (TLR)4 agonist formulation, to adjuvant Fluzone® in mice and non-human primates. The GLA-SE adjuvanted Fluzone vaccine caused no adverse reactions, increased the induction of T helper type 1 (TH1)-biased cytokines such as IFNγ, TNF and IL-2, and broadened serological responses against drifted A/H1N1 and A/H3N2 influenza variants. These results suggest that synthetic TLR4 adjuvants can enhance the magnitude and quality of protective immunity induced by influenza vaccines.

1 June 2019 in Patient Related Outcome Measures
Verified
Journal Article
Open access
PDF file
ECEric M Chang
Eric M Chang
EGErin F Gillespie
Erin F Gillespie
NSNarek Shaverdian
Narek Shaverdian
The use of patient-reported outcome (PRO) measures in research and clinical care has expanded dramatically, reflective of an increasing recognition of patient-centeredness as an important aspect of high-quality health care. Given this rapid expansion, ensuring that data collected using PRO measures is of high quality is crucial for their continued successful application. Because of the subjective nature of the outcomes assessed, there are many factors that may influence patients’ responses and thus challenge the overall quality of the data. In this review, we discuss the multiple factors that may affect patients’ responses on PRO measures. These factors may arise during instrument development and administration or secondary to patient-level response behaviors. We further examine the relevant literature to delineate how these factors may impact data quality and review methods for accounting for these factors. Consideration of such factors is critical to ensuring data collected truthfully reflects patients’ evaluations and provides accurate conclusions.

1 October 2009 in Vaccine
Verified
Journal Article
Closed access
SBSusan L. Baldwin
Susan L. Baldwin
NSNarek Shaverdian
Narek Shaverdian
YGYasuyuki Goto
Yasuyuki Goto
MDMalcolm Duthie
Malcolm Duthie
VRVanitha S. Raman
Vanitha S. Raman
SRSteven G. Reed
Steven G. Reed

1 January 2010 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
RARyan C. Anderson
Ryan C. Anderson
CFChristopher B. Fox
Christopher B. Fox
TDTimothy S. Dutill
Timothy S. Dutill
NSNarek Shaverdian
Narek Shaverdian
TETara L. Evers
Tara L. Evers
TVThomas S. Vedvick
Thomas S. Vedvick